Merck & Co., Inc. (MRK)

US — Healthcare Sector
Peers: NVO  NVS  ABT  GILD  PFE  AMGN  AZN  TMO  SNY  GSK 

Automate Your Wheel Strategy on MRK

With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol MRK
  • Rev/Share 25.7146
  • Book/Share 20.7566
  • PB 4.1794
  • Debt/Equity 0.798
  • CurrentRatio 1.6612
  • ROIC 0.2431

 

  • MktCap 218020510675.0
  • FreeCF/Share 5.2238
  • PFCF 16.7078
  • PE 11.385
  • Debt/Assets 0.372
  • DivYield 0.0373
  • ROE 0.3895

 

  • Rating A-
  • Score 4
  • Recommendation Buy
  • P/E Score 3
  • DCF Score 5
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed MRK Citigroup -- Neutral -- $95 Oct. 13, 2025
Downgrade MRK Berenberg Buy Hold -- $90 Sept. 17, 2025
Downgrade MRK Citigroup Buy Neutral -- $84 May 14, 2025
Initiation MRK Cantor Fitzgerald -- Neutral -- $85 April 22, 2025
Downgrade MRK Deutsche Bank Buy Hold $128 $105 Feb. 18, 2025
Downgrade MRK TD Cowen Buy Hold $121 $100 Feb. 10, 2025
Downgrade MRK Truist Buy Hold -- $110 Jan. 8, 2025
Downgrade MRK BMO Capital Markets Outperform Market Perform $136 $105 Dec. 20, 2024
Resumed MRK BofA Securities -- Buy -- $121 Dec. 10, 2024
Upgrade MRK HSBC Securities Hold Buy -- $130 Dec. 4, 2024

News

Shareholders that lost money on Merck & Co., Inc.(MRK) should contact Levi & Korsinsky about pending Class Action - MRK
MRK
Published: April 03, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / April 3, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=140774&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Shareholders that lost money on Merck & Co., Inc.(MRK) should contact Levi & Korsinsky about pending Class Action - MRK
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines – MRK
MRK
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. (“Merck” or the “Company”) (NYSE: MRK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines – MRK
MRK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
MRK
Published: April 03, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or "the Company") (NYSE:MRK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Merck securities between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period").

Read More
image for news MRK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact The Gross Law Firm
MRK
Published: April 03, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , April 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK). Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Read More
image for news Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact The Gross Law Firm
Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
MRK
Published: April 02, 2025 by: PRNewsWire
Sentiment: Neutral

LOS ANGELES , April 2, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Merck & Co ("Merck" or the "Company") (NYSE: MRK) have opportunity to lead the securities fraud class action lawsuit.

Read More
image for news Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters
LLY, MRK, PFE
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Negative

Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.

Read More
image for news PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
MRK
Published: April 02, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE:MRK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK
MRK
Published: April 02, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=140454&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK
MRK Investors Have Final Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm
MRK
Published: April 02, 2025 by: PRNewsWire
Sentiment: Neutral

LOS ANGELES , April 2, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Merck & Co., Inc. ("Merck" or "the Company") (NYSE: MRK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 3, 2022, and February 3, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before April 14, 2025.

Read More
image for news MRK Investors Have Final Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
ABBV, AMGN, BMY, GILD, LLY, MRK, MRNA, PFE, VRTX
Published: April 01, 2025 by: CNBC
Sentiment: Negative

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'

Read More
image for news Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact Levi & Korsinsky
MRK
Published: April 01, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=140221&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact Levi & Korsinsky
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
AZN, MRK
Published: April 01, 2025 by: CNBC
Sentiment: Positive

AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

Read More
image for news Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck Lawsuit – MRK
MRK
Published: April 01, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Merck investors who were adversely affected by alleged securities fraud between February 3, 2022 and February 3, 2025.

Read More
image for news Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck Lawsuit – MRK
Investors in Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK
MRK
Published: April 01, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=140201&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Investors in Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
MRK
Published: April 01, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE:MRK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
Bernstein's Courtney Breen: Merck, Novo Nordisk, others at high risk from tariffs
MRK, NVO, ABBV, GSK, SNY
Published: April 01, 2025 by: CNBC Television
Sentiment: Negative

Courtney Breen, Bernstein senior analyst, joins CNBC's 'Money Movers' to discuss how to draw the line between tariff risks and company financials in pharmaceuticals, which companies are most at risk, and more.

Read More
image for news Bernstein's Courtney Breen: Merck, Novo Nordisk, others at high risk from tariffs
Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRK
MRK
Published: March 31, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 31, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=140025&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRK
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
MRK
Published: March 28, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 28, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Merck securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Read More
image for news ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK
MRK
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=139205&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK
TOP RANKED ROSEN LAW FIRM Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
MRK
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 27, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Merck securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Read More
image for news TOP RANKED ROSEN LAW FIRM Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck & Co., Inc. Lawsuit - MRK
MRK
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/merck-co-inc-lawsuit-submission-form?prid=139197&wire=1 or contact Joseph E. Levi, Esq.

Read More
image for news Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Merck & Co., Inc. Lawsuit - MRK
Investors who lost money on Merck & Co., Inc. (MRK) should contact Levi & Korsinsky about pending Class Action - MRK
MRK
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) of a class action securities lawsuit.

Read More
image for news Investors who lost money on Merck & Co., Inc. (MRK) should contact Levi & Korsinsky about pending Class Action - MRK
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK
MRK
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the “Class Period”), of the important April 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Merck securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Read More
image for news ROSEN, LEADING TRIAL ATTORNEYS, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK
Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
MRK
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral

LOS ANGELES , March 27, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Merck & Co ("Merck" or the "Company") (NYSE: MRK). IF YOU SUFFERED A LOSS ON YOUR MERCK INVESTMENTS, CLICK HERE BEFORE APRIL 14, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?

Read More
image for news Merck & Co (MRK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
MRK
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or the "Company") (NYSE:MRK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK
MRK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
MRK
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or "the Company") (NYSE:MRK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Merck securities between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period").

Read More
image for news MRK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Class Action Filed Against Merck & Co., Inc. (MRK) - April 14, 2025 Deadline to Join - Contact The Gross Law Firm
MRK
Published: March 27, 2025 by: PRNewsWire
Sentiment: Neutral

NEW YORK , March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Merck & Co., Inc. (NYSE: MRK). Shareholders who purchased shares of MRK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Read More
image for news Class Action Filed Against Merck & Co., Inc. (MRK) - April 14, 2025 Deadline to Join - Contact The Gross Law Firm
Forget S&P 500 And Buy These Dividend Icons Instead
ES, MRK, SPY
Published: March 26, 2025 by: Seeking Alpha
Sentiment: Positive

The S&P 500's high valuation and low yield make it unappealing for value and income investors. In this article, I highlight 2 durable dividend stocks that support far higher yields that are well-supported by cashflows. Both have long track records of raising their payouts and are far more attractively valued than the S&P 500.

Read More
image for news Forget S&P 500 And Buy These Dividend Icons Instead
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines – MRK
MRK
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Merck & Co., Inc. (“Merck” or the “Company”) (NYSE: MRK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

Read More
image for news INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines – MRK
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
MRK
Published: March 26, 2025 by: Accesswire
Sentiment: Neutral

NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or "the Company") (NYSE:MRK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Merck securities between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period").

Read More
image for news MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!

About Merck & Co., Inc. (MRK)

  • IPO Date 1978-01-13
  • Website https://www.merck.com
  • Industry Drug Manufacturers - General
  • CEO Robert M. Davis
  • Employees 73000

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.